254 related articles for article (PubMed ID: 36702689)
21. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
[TBL] [Abstract][Full Text] [Related]
22. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
[TBL] [Abstract][Full Text] [Related]
23. Hypo-methylation mediates chromosomal instability in pancreatic NET.
Marinoni I; Wiederkeher A; Wiedmer T; Pantasis S; Di Domenico A; Frank R; Vassella E; Schmitt A; Perren A
Endocr Relat Cancer; 2017 Mar; 24(3):137-146. PubMed ID: 28115389
[TBL] [Abstract][Full Text] [Related]
24. Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.
Kim HS; Lee HS; Nam KH; Choi J; Kim WH
Anticancer Res; 2015 Jun; 35(6):3501-10. PubMed ID: 26026117
[TBL] [Abstract][Full Text] [Related]
25. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases.
Pea A; Yu J; Marchionni L; Noe M; Luchini C; Pulvirenti A; de Wilde RF; Brosens LA; Rezaee N; Javed A; Chianchiano P; Gobbo S; Regi P; Salvia R; Bassi C; He J; Weiss MJ; Cameron JL; Offerhaus GJA; Hruban RH; Lawlor RT; Scarpa A; Heaphy CM; Wood LD; Wolfgang CL
Ann Surg; 2020 Mar; 271(3):566-573. PubMed ID: 30339629
[TBL] [Abstract][Full Text] [Related]
26. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.
Liau JY; Lee JC; Tsai JH; Yang CY; Liu TL; Ke ZL; Hsu HH; Jeng YM
Mod Pathol; 2015 Dec; 28(12):1545-54. PubMed ID: 26428317
[TBL] [Abstract][Full Text] [Related]
28. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
[TBL] [Abstract][Full Text] [Related]
29.
Baek J; Jang NR; Shim YR; Gu MJ
Indian J Pathol Microbiol; 2022; 65(3):598-603. PubMed ID: 35900487
[TBL] [Abstract][Full Text] [Related]
30. CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors.
McGovern JM; Singhi AD; Borhani AA; Furlan A; McGrath KM; Zeh HJ; Bahary N; Dasyam AK
AJR Am J Roentgenol; 2018 Nov; 211(5):1020-1025. PubMed ID: 30160983
[TBL] [Abstract][Full Text] [Related]
31. New Genetics and Genomic Data on Pancreatic Neuroendocrine Tumors: Implications for Diagnosis, Treatment, and Targeted Therapies.
Schmitt AM; Marinoni I; Blank A; Perren A
Endocr Pathol; 2016 Sep; 27(3):200-4. PubMed ID: 27456058
[TBL] [Abstract][Full Text] [Related]
32. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation?
Marinoni I
Gut; 2022 May; 71(5):847-848. PubMed ID: 33975869
[No Abstract] [Full Text] [Related]
34. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
[TBL] [Abstract][Full Text] [Related]
35. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors.
Yadav R; Kakkar A; Sharma A; Malik PS; Sharma MC
Scand J Gastroenterol; 2016 Aug; 51(8):994-9. PubMed ID: 27162024
[TBL] [Abstract][Full Text] [Related]
36. Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas.
Sun C; Estrella JS; Whitley EM; Chau GP; Lozano G; Wasylishen AR
Dis Model Mech; 2022 Aug; 15(8):. PubMed ID: 35976056
[TBL] [Abstract][Full Text] [Related]
37. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
38. Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT).
Neyaz A; Crotty R; Rickelt S; Pankaj A; Stojanova M; Michelakos TP; Sekigami Y; Kontos F; Parrack PH; Patil DT; Heaphy CM; Ferrone CR; Deshpande V
Histopathology; 2023 Oct; 83(4):546-558. PubMed ID: 37455385
[TBL] [Abstract][Full Text] [Related]
39. ATRX affects the repair of telomeric DSBs by promoting cohesion and a DAXX-dependent activity.
Lovejoy CA; Takai K; Huh MS; Picketts DJ; de Lange T
PLoS Biol; 2020 Jan; 18(1):e3000594. PubMed ID: 31895940
[TBL] [Abstract][Full Text] [Related]
40. Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
Alzoubi H; Minasi S; Gianno F; Antonelli M; Belardinilli F; Giangaspero F; Jaffrain-Rea ML; Buttarelli FR
Endocr Pathol; 2022 Dec; 33(4):494-505. PubMed ID: 34993885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
